Skip to main content

Women at Risk for Pregnancy

3
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sebela Pharmaceuticals
2 programs
2
VeraCeptPhase 31 trial
VeraCeptPhase 31 trial
Active Trials
NCT03785366Completed41Est. Aug 2024
NCT03633799Active Not Recruiting1,620Est. Sep 2027
Syneos Health
Syneos HealthNC - Morrisville
1 program
1
VeraCeptPhase 3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Sebela PharmaceuticalsVeraCept
Sebela PharmaceuticalsVeraCept

Clinical Trials (2)

Total enrollment: 1,661 patients across 2 trials

A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)

Start: Dec 2018Est. completion: Aug 202441 patients
Phase 3Completed

Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS

Start: Aug 2018Est. completion: Sep 20271,620 patients
Phase 3Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.